Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.

12 Moreover, in this setting, two randomized trials reported that the combination of carboplatin–gemcitabine–bevacizumab or carboplatin–paclitaxel–bevacizumab administered until progression of disease, significantly increases PFS with an hazard ratio of 0.48 13 with a nonsignificant trend in OS increase (hazard ratio 0.82). 14 However, the unsatisfactory results obtained with salvage chemotherapy have elicited investigators to detect novel biological agents capable of achieving a better control of the disease. 15 In the last two decades several changes in all fields of ovarian cancer management have occurred, from the diagnosis, to the treatment, to the translational research.

also in 5,406 other papers